Completed enrollment in global pivotal Phase 3 study for firmonertinib monotherapy in first-line NSCLC harboring EGFR exon 20 insertion mutationsPlanned update for development of firmonertinib in first-line NSCLC PACC mutations in Q2 2025First IND for ARR-217 (MRG007), an antibody drug conjugate (ADC) targeting CDH17, submitted in China Cash, cash equivalents and marketable securities of $205.5 million as of March 31, 2025 NEWTOWN SQUARE, Pa., May 12, 2025 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (NASDAQ:AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today reported financial results

NEWTOWN SQUARE, Pa., April 28, 2025 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (NASDAQ:AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced the appointment of Merdad Parsey, M.D., Ph.D. to its Board of Directors. Dr. Parsey brings decades of executive experience leading global clinical development in the biopharmaceutical industry, most recently serving as Chief Medical Officer and Executive Vice President of Gilead Sciences, Inc. "Dr. Parsey is a seasoned executive who has driven therapeutic innovation and strategic growth at prominent pharmaceutical and biotech companies acr

First clinical data demonstrating robust confirmed responses and CNS anti-tumor activity for firmonertinib in first-line NSCLC EGFR PACC mutationsGlobal pivotal Phase 3 monotherapy study for firmonertinib in first-line NSCLC harboring EGFR exon 20 insertion mutations achieved target enrollmentSelected next-generation ADC candidate ARR-002 for IND enabling studiesCash and cash equivalents of $266.5 million as of December 31, 2024 NEWTOWN SQUARE, Pa., March 03, 2025 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (NASDAQ:AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today reported financia

Exclusive global license outside of Greater China for MRG007, a novel antibody drug conjugate (ADC) in development for gastrointestinal (GI) cancersFirst Investigational New Drug (IND) submission planned for 1H 2025Expands ArriVent's growing pipeline of next-generation ADCs NEWTOWN SQUARE, Pa. and SHANGHAI, Jan. 21, 2025 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (NASDAQ:AVBP) a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced that it has entered into an exclusive license agreement with Lepu Biopharma Co., Ltd (Stock Code: 02157.HK) for MRG007, an antibody-drug conjugate (ADC) th

Robust firmonertinib monotherapy activity in front-line EGFR PACC mutant NSCLC including in patients with brain metastases Top-line pivotal data from global Phase 3 FURVENT trial for firmonertinib in front-line NSCLC harboring EGFR exon 20 insertion mutations expected 2025 Cash and cash equivalents of $282.9 million as of September 30, 2024 NEWTOWN SQUARE, Pa., Nov. 14, 2024 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (NASDAQ:AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today reported financial results for the third quarter ended September 30, 2024, and highlighted recent Company pr

81.8% ORR by BICR and 63.6% confirmed ORR by BICR at the 240 mg dose; 46.2% confirmed ORR in CNS Metastases 90.9% (n = 20/22) of patients with confirmed responses remained on study with a median duration of response not yet reached at time of analysis ArriVent to host virtual webinar on these interim analyses of Phase 1b data for firmonertinib in EGFR PACC mutant NSCLC on September 9, 2024 at 4:30 pm ET NEWTOWN SQUARE, Pa., Sept. 09, 2024 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (NASDAQ:AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced positive proof-of-concept randomiz

Clinical proof-of-concept monotherapy data for once daily, first-line firmonertinib in EGFR PACC mutant non-small cell lung cancer (NSCLC) to be presented as a presidential symposium presentation at the 2024 World Conference on Lung Cancer (WCLC) ArriVent to host virtual webinar on these interim analyses of Phase 1b data for firmonertinib in EGFR PACC mutant NSCLC in conjunction with 2024 WCLC on September 9, 2024 at 4:30pm ET Entered into a multi-target antibody drug conjugate (ADC) collaboration agreement with Alphamab expanding ArriVent's ADC portfolio and oncology focused pipeline NEWTOWN SQUARE, Pa., Aug. 14, 2024 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or

First-line monotherapy data for once daily firmonertinib selected as an oral presentation in the presidential session       First prospectively designed randomized clinical data for a small-molecule EGFR tyrosine kinase inhibitor in PACC mutant non-small cell lung cancer patient population       ArriVent to host virtual webinar in conjunction with 2024 WCLC NEWTOWN SQUARE, Pa., Aug. 12, 2024 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (NASDAQ:AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced it will present interim randomized Phase 1b FURTHER data for first-line firmonert

Collaboration will leverage Alphamab's antibody drug conjugate ("ADC") research and discovery platform and ArriVent's global development and commercialization expertise Upfront and milestone payments to Alphamab worth up to $615.5 million for potential ADCs SUZHOU, China and NEWTOWN SQUARE, Pa., June 05, 2024 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc., ("ArriVent") a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced that the Company has entered into a collaboration agreement with Jiangsu Alphamab Biopharmaceuticals Co., Ltd. ("Alphamab"), a wholly owned subsidiary of Alphamab Oncology, to discover,

NEWTON SQUARE, Pa., May 16, 2024 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc., a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced the appointment of John Hohneker, M.D. to its Board of Directors. Dr. Hohneker brings over 30 years of experience in biopharmaceutical leadership and drug development, and currently serves on the Boards of public companies Carisma Therapeutics, Inc. and Curis, Inc., and private companies Sonata Therapeutics and Trishula Therapeutics. "We are excited to welcome Dr. Hohneker to our Board of Directors and look forward to his partnership as we work to advance our pipeline, includin

10-Q - ArriVent BioPharma, Inc. (0001868279) (Filer)

8-K - ArriVent BioPharma, Inc. (0001868279) (Filer)

DEFA14A - ArriVent BioPharma, Inc. (0001868279) (Filer)

DEF 14A - ArriVent BioPharma, Inc. (0001868279) (Filer)

8-K - ArriVent BioPharma, Inc. (0001868279) (Filer)

8-K - ArriVent BioPharma, Inc. (0001868279) (Filer)

S-8 - ArriVent BioPharma, Inc. (0001868279) (Filer)

8-K - ArriVent BioPharma, Inc. (0001868279) (Filer)

10-K - ArriVent BioPharma, Inc. (0001868279) (Filer)

SCHEDULE 13G - ArriVent BioPharma, Inc. (0001868279) (Subject)

4 - ArriVent BioPharma, Inc. (0001868279) (Issuer)

3 - ArriVent BioPharma, Inc. (0001868279) (Issuer)

4 - ArriVent BioPharma, Inc. (0001868279) (Issuer)

4 - ArriVent BioPharma, Inc. (0001868279) (Issuer)

4 - ArriVent BioPharma, Inc. (0001868279) (Issuer)

4 - ArriVent BioPharma, Inc. (0001868279) (Issuer)

4 - ArriVent BioPharma, Inc. (0001868279) (Issuer)

4 - ArriVent BioPharma, Inc. (0001868279) (Issuer)

4 - ArriVent BioPharma, Inc. (0001868279) (Issuer)

3 - ArriVent BioPharma, Inc. (0001868279) (Issuer)

B. Riley Securities initiated coverage of ArriVent BioPharma with a rating of Buy and set a new price target of $37.00

Guggenheim initiated coverage of ArriVent BioPharma with a rating of Buy and set a new price target of $45.00

Oppenheimer initiated coverage of ArriVent BioPharma with a rating of Outperform and set a new price target of $35.00

H.C. Wainwright initiated coverage of ArriVent BioPharma with a rating of Buy and set a new price target of $25.00

Jefferies initiated coverage of ArriVent BioPharma with a rating of Buy and set a new price target of $35.00

Goldman initiated coverage of ArriVent BioPharma with a rating of Buy and set a new price target of $27.00

Citigroup initiated coverage of ArriVent BioPharma with a rating of Buy and set a new price target of $30.00

Completed enrollment in global pivotal Phase 3 study for firmonertinib monotherapy in first-line NSCLC harboring EGFR exon 20 insertion mutationsPlanned update for development of firmonertinib in first-line NSCLC PACC mutations in Q2 2025First IND for ARR-217 (MRG007), an antibody drug conjugate (ADC) targeting CDH17, submitted in China Cash, cash equivalents and marketable securities of $205.5 million as of March 31, 2025 NEWTOWN SQUARE, Pa., May 12, 2025 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (NASDAQ:AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today reported financial results

NEWTOWN SQUARE, Pa., April 28, 2025 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (NASDAQ:AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced the appointment of Merdad Parsey, M.D., Ph.D. to its Board of Directors. Dr. Parsey brings decades of executive experience leading global clinical development in the biopharmaceutical industry, most recently serving as Chief Medical Officer and Executive Vice President of Gilead Sciences, Inc. "Dr. Parsey is a seasoned executive who has driven therapeutic innovation and strategic growth at prominent pharmaceutical and biotech companies acr

NEWTON SQUARE, Pa., May 16, 2024 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc., a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced the appointment of John Hohneker, M.D. to its Board of Directors. Dr. Hohneker brings over 30 years of experience in biopharmaceutical leadership and drug development, and currently serves on the Boards of public companies Carisma Therapeutics, Inc. and Curis, Inc., and private companies Sonata Therapeutics and Trishula Therapeutics. "We are excited to welcome Dr. Hohneker to our Board of Directors and look forward to his partnership as we work to advance our pipeline, includin

NEWTON SQUARE, Pa., April 22, 2024 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc., a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced the appointment of Kristine Peterson to its Board of Directors. Ms. Peterson brings over 30 years of biopharmaceutical leadership experience, and currently serves on the Boards of public companies Immunocore, Inc. and Enanta Pharmaceuticals. "We are thrilled for Kris to join our Board of Directors at such an important time for ArriVent, as we advance the development of firmonertinib in multiple non-small cell lung cancer ("NSCLC") indications," said Bing Yao, Chairman and C

SC 13G - ArriVent BioPharma, Inc. (0001868279) (Subject)

SC 13G - ArriVent BioPharma, Inc. (0001868279) (Subject)

SC 13G - ArriVent BioPharma, Inc. (0001868279) (Subject)

SC 13G - ArriVent BioPharma, Inc. (0001868279) (Subject)

SC 13G - ArriVent BioPharma, Inc. (0001868279) (Subject)